CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| ANBL0421 | COG | A Phase II Study of Irinotecan + Temozolomide in Children with Recurrent Neuroblastoma: A Groupwide Phase II Study | Pediatric CIRB | Completed |
| AEWS1221 | COG | Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479; NSC# 750008; IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma | Pediatric CIRB | Available to Open |
| AAML07P1 | COG | A Phase II Pilot Study of Bortezomib (PS-341; Velcade; IND# 58;443) Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent; Refractory or Secondary Acute Myeloid Leukemia | Pediatric CIRB | Completed |
| ALTE16C1 | COG | Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma | Pediatric CIRB | Available to Open |
| ADVL1221 | COG | A Phase II Study of Cixutumumab (IMC-A12; IND# 100947) in Combination with Temsirolimus (IND# 61010) in Pediatric Patients with Recurrent or Refractory Solid Tumors | Pediatric CIRB | Completed |
| ACCL10P1 | COG | Computerized Cognitive Training for Pediatric Brain Tumor Patients: A Pilot Study | Pediatric CIRB | Available to Open |
| AALL03B1 | COG | Classification of Acute Lymphoblastic Leukemia | Pediatric CIRB | Completed |
| AOST2032 | COG | A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma | Pediatric CIRB | Available to Open |
| AOST0331 | COG | A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (IND# 12697): A Phase III Intergroup Study | Pediatric CIRB | Completed |
| ANBL1531 | COG | A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) | Pediatric CIRB | Available to Open |